Dallas, Texas--(Newsfile Corp. - September 30, 2022) - Bio-Path Holdings, Inc. (Nasdaq: BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q2FY22.pdf
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Bio-Path's pipeline continues to expand with new cancer indications
- Bio-Pathhas completed Phase 1 clinical trials for its lead candidate prexigebersen for AML and other blood cancers
- The Company most recently reported that cash on hand as of 6/30/22 is sufficient to fund operations according to plan for at the next 12 months
Click image above to view full announcement.
About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/139051
